Načítá se...
Reduced Dose Ibrutinib Due to Financial Toxicity in CLL
Ibrutinib is the only approved novel agent that is available for the treatment of relapsed-refractory and treatment-naive chronic lymphocytic leukemia patients with deletion 17p or TP53 mutation in India. The cost of ibrutinib is still prohibitive for most Indian CLL patients. We report here for the...
Uloženo v:
| Vydáno v: | Indian J Hematol Blood Transfus |
|---|---|
| Hlavní autoři: | , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Springer India
2018
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6439022/ https://ncbi.nlm.nih.gov/pubmed/30988561 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12288-018-1011-4 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|